If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
236
results.
Updated on
14/07/2025 [06:52:00]
Results 150 to 175 of 236
Absstract of: US2025213677A1
Proposed is a drug-delivery composition including plant-derived nanovesicles as an active ingredient. It was confirmed that antigen (drug) delivery efficiency is higher when the antigens are loaded into nanovesicles isolated from grapefruits or mandarin oranges, and the loaded antigens are administered rather than administering hepatitis B virus surface antigens (HBsAg) alone. Thus, the nanovesicles can be useful as a drug-delivery composition.
Absstract of: US2025213498A1
According to some embodiments, a method of providing treatment of a host comprises binding a carrier to cell structures of cells of the host to reduce a likelihood of an agent binding to said cell structures to at least partially inhibits the agent from binding to said cell structures, wherein the carrier comprises a core and a surface functionalized on the core, wherein the functionalized surface bind to target areas of cell structures of the host's cells, and wherein the carrier is to be used as targeted treatment for one or more disease, infections or allergic reactions caused by a disease-causing agent or source.
Absstract of: US2025213493A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Absstract of: US2025213696A1
An example provides a biodegradable upconversion nanoparticle with a core-double shell structure including: a core layer; an inorganic host matrix outer shell layer; and a transition layer positioned between the core layer and the outer shell layer and functioning as an energy transfer network, wherein the core layer, the outer shell layer, and the transition layer are biodegradable. By means of such a structure, a long decomposition time and high luminescent efficiency are ensured, and thus the biodegradable upconversion nanoparticle may remain in an organism body for a long time to allow the effect to persist.
Absstract of: AU2023409835A1
The present disclosure provides lipid nanoparticles having a sphere like structure, compositions comprising the lipid nanoparticles and methods for delivery of the agents. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
Absstract of: AU2023409836A1
The present disclosure relates compositions of RNA encapsulated in lipid nanoparticles and methods of producing the same The compositions can be used for delivery of mRNA to a subject. The lipid nanoparticles have improved properties for delivery of biologically active agents, such as RNA.
Absstract of: US2025213497A1
The present invention relates to a nano-in micro formulation, capable of enhancing the oral bioavailability of drugs. Said formulation is made of a drug loaded composite nanoparticles made of protein-polymer, which is embedded within a microsystem (nano-in micro) made of multiple layers, each layer serving specific function such as enteric protection, muco-adhesion, muco-penetration, release modification, efflux inhibition, all functions collectively resulting in the enhanced bioavailability of loaded drug by at least two-fold when compared with control free drug. The present invention also discloses the process for conceiving said nano-in micro formulation and describes the use of said nano-in micro formulation in the treatment of cancer and other diseases.
Absstract of: AU2023401698A1
Provided herein are pharmaceutical compositions comprising surface functionalized carbon nanotube and an active agent. The active agent can be attached to the carbon nanotube covalently or noncovalently. Also provided are methods of preparing the pharmaceutical compositions and methods of use thereof.
Absstract of: JP2021181568A
To provide polymer and polymer conjugate-based nanoparticle delivery systems for delivering biological agents, and methods of making and using these compositions.SOLUTION: The present disclosure provides polymers comprising alternating charged and uncharged segments comprising one or more of the following structural units of Formula (I) or Formula (II) or Formula (III), where A is an uncharged segment comprising polyalkylene glycol; and B is a cationically charged segment comprising one polyhydroxy linkage including at least a pair of adjacent diols.SELECTED DRAWING: Figure 10
Absstract of: WO2025140594A1
The present invention belongs to the field of drug delivery. Provided is an asymmetric cationic lipid containing multiple tertiary amines, of which the structure is shown as a general formula (1), wherein the definition of each symbol is consistent with that in the description. In the present invention, a degradable group is introduced into a proper position of the cationic lipid, and the presence of the degradable group enables an LNP-drug composition prepared from the cationic lipid to be degradable in endosomes at a proper time and to have small cytotoxicity, thereby solving the problem that in the prior art, LNP-drug compositions prepared from non-degradable lipids will accumulate in endosomes and acidify the endosomal environment, which hinders the endosomal escape of drugs (such as mRNAs) and causes that the drugs delivered into cells fail to sufficiently exert the therapeutic effects. The cationic lipid in the present invention uses a heterofunctionalized piperazine-containing small molecule as a raw material, involves a simple preparation process and a lower cost, and is more green and environmentally-friendly. An LNP-mRNA composition prepared from the cationic lipid has the advantages of low toxicity, high biocompatibility, high cell transfection, etc.
Absstract of: WO2025140596A1
The present invention provides an ionizable cationic lipid compound having a structure as represented by formula (I). The compound can be used for preparing lipid nanoparticles (LNPs) for delivery of a therapeutic agent and/or a preventive agent. The LNPs prepared using the ionizable cationic lipid compound of the present invention have high stability and transfection efficiency, and can efficiently and stably deliver biologically active substances (including a nucleic acid, such as mRNA) to target cells or organs, thereby inducing a highly specific antibody response in vivo.
Absstract of: WO2025140501A1
An apalutamide nanoparticle and preparation method therefor relating to the field of pharmaceutical preparations. The nanoparticle comprises an active ingredient and a stabilizer. The active ingredient is amorphous apalutamide or a pharmaceutically acceptable salt thereof, and the stabilizer comprises an ionic stabilizer and a steric stabilizer. The provided nanoparticle has a stable physical form, is able to stably maintain an amorphous crystal form, has good dissolution speed and dissolution rate, possesses good stability in terms of dissolution, content, related substances, crystal form, etc., and has good bioavailability.
Absstract of: WO2025140529A1
The present invention pertains to the technical field of pharmaceutical preparations, and provides a novel solution-type quetiapine composition for transnasal administration. In the provided composition, quetiapine is completely dissolved therein in the form of a solution and administered transnasally. Compared with oral dosage forms on the market, the provided quetiapine solution-type transnasal preparation has particularly useful pharmacokinetic and pharmacodynamic profiles. Compared with other disclosed transnasal nano-emulsion forms, the composition of the present invention still has surprising pharmacokinetic and pharmacodynamic profiles, shows good clinical application prospects, and is expected to meet unmet clinical needs. On this basis, the present invention also provides a further improved high-saturation dissolution concentration technical solution and a further improved good chemical stability technical solution for preparing the quetiapine solution-type transnasal preparation.
Absstract of: CN119451667A
The invention belongs to the technical field of pain relief, and relates to a pharmaceutical composition which comprises at least one anesthetic. The anesthetic is selected from the group consisting of ropivacaine, bupivacaine, eticaine, levobupivacaine, lidocaine, linocaine, mepivacaine, articaine, dibuvacaine, levobupivacaine, prilocaine, benzocaine, cloprocaine, cocaine, procaine, promecaine, tetracaine, and any pharmaceutically acceptable salts, hydrates thereof, as well as pharmaceutically acceptable salts, hydrates thereof. A solvate or a prodrug; at least one alkanolamine selected from the group consisting of: triethanolamine, tripropanolamine, and trimethylamine; water; and optionally a pharmaceutically acceptable diluent, carrier and/or excipient. The disclosure also relates to the use of the composition for providing pain relief, methods of treatment, methods of producing the pharmaceutical composition, and carbon quantum dots formed from the components of the pharmaceutical composition.
Absstract of: CN119907694A
The present invention relates to a polynucleotide comprising at least one miR-124 target sequence, and/or at least one miR-338-3p target sequence, and/or at least one miR-31 target sequence wherein the miRNA target sequence is operably linked to a transgene.
Absstract of: MX2024015534A
Compositions and methods for reducing MHC class I protein expression in a cell comprising genetically modifying MHC class I for use <i>e.g</i>., in adoptive cell transfer therapies.
Absstract of: CN119421946A
A neutrophil expressing a chimeric antigen receptor (CAR) and loaded with nanoparticles comprising a drug; and methods of treating cancer or other conditions in a subject comprising administering to the subject a therapeutically effective amount of a CAR-expressing neutrophil.
Absstract of: US2025108009A1
A method for synthesizing hybrid nanoparticles comprising apolipoproteins uses a swirling microvortex device. The hybrid nanoparticles include proteins that include apolipoproteins and have various functionalities. The production method can be used to produce small, uniform, stable nanoparticles having various physiological activities.
Absstract of: WO2023244803A1
This application relates in part to nanoparticles comprising a tobamovirus and nanoparticles comprising a tobamovirus and beta-cyclodextrin (β-CD or BCD). This application also relates in part to nanoparticles comprising tobamovirus and one or more active ingredients (AIs) that are non-covalently conjugated to the tobamovirus. The application also provides methods of making and methods of using such nanoparticles as well as compositions comprising the disclosed nanoparticles.
Absstract of: WO2025140421A1
The present invention belongs to the technical field of biomedicine, and specifically relates to an ionizable lipid compound and a use thereof in delivering a nucleic acid vaccine. Provided is the ionizable lipid compound represented by formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof. The definition of each group in the formula is described in detail.
Absstract of: WO2025144636A1
The present invention provides engineered human metapneumovirus (hMPV) F protein trimer immunogens. These engineered proteins are stabilized via specific modifications introduced into both the F2 subunit and the F1 subunit of a wildtype hMPV soluble F sequence, e.g., shortened F2 subunit C -terminus and interprotomer disulfide bond in the F1 subunit. Also provided in the invention are nanoparticle vaccines that contain the engineered hMPV soluble F immunogens displayed on self-assembling nanoparticles. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating hMPV infections.
Absstract of: WO2025143844A1
The present invention provides a pharmaceutical composition in which perfluorocarbon is formulated in the form of a nanoemulsion using casein or a salt thereof, and a preparation method therefor. In the pharmaceutical composition of the present invention, perfluorocarbon may be present in the form of stable liquid particles in the nanoemulsion. Therefore, the pharmaceutical composition of the present invention can avoid side effects such as thrombus formation or vascular occlusion, and thus can be useful as an artificial oxygen carrier, i.e., a blood substitute.
Absstract of: WO2025143853A1
The present invention relates to a composition for drug delivery, and a preparation method therefor, and, more specifically, to a composition for drug delivery, and a preparation method therefor, the composition having a form such that a drug is encapsulated inside a nanoparticle structure formed by a polymer and a cationic lipid with a specific structure.
Absstract of: WO2025143842A1
The present invention relates to a pharmaceutical composition for an artificial oxygen carrier comprising plant exosomes containing hemoglobin or a derivative thereof, and a preparation method therefor and, more specifically, to: a pharmaceutical composition having an oxygen carrier function by preparing exosomes from plants containing antioxidant enzymes, removing enzyme and protein components to 10% or less in the prepared exosomes to improve safety when injected into the body, and encapsulating hemoglobin or a derivative thereof; and a preparation method therefor.
Nº publicación: WO2025143286A1 03/07/2025
Applicant:
NANOMEDI PHARM CO LTD [KR]
\uC8FC\uC2DD\uD68C\uC0AC \uB098\uB178\uBA54\uB514\uD31C
Absstract of: WO2025143286A1
The present invention relates to a nano-drug delivery platform loaded with an ultra-small anticancer drug having multiple mechanisms of action, a pharmaceutical composition containing same, and a preparation method therefor. The present invention can provide a drug carrier-based ultra-small anticancer agent, which enables treatment even at dosages lower than that of complete anticancer drugs used in a conventional clinical trial, and thus has no effect on normal tissue and achieves high patient compliance, and can reduce side effects during or after treatment.
BOPI
Electronic site
